Kensuke Tateishi Selected Research

Coenzymes (Enzyme Cofactors)

1/2021	Sirtuin activation targets IDH-mutant tumors.
1/2017	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity.
12/2015	Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kensuke Tateishi Research Topics

Disease

14	Neoplasms (Cancer) 01/2021 - 03/2013
10	Glioma (Gliomas) 01/2022 - 08/2013
3	Glioblastoma (Glioblastoma Multiforme) 01/2021 - 09/2016
2	Lymphoma (Lymphomas) 07/2021 - 12/2020
1	Medulloblastoma 01/2021
1	Astrocytoma (Pilocytic Astrocytoma) 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 06/2020
1	Neuroepithelial Neoplasms (Gliomatosis Cerebri) 01/2020
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 10/2019
1	Aneurysm (Aneurysms) 09/2019
1	Intracranial Aneurysm (Cerebral Aneurysm) 09/2019
1	Oligodendroglioma 01/2019
1	Spinal Cord Compression 01/2019
1	Spinal Cord Diseases 01/2019
1	Kyphosis 12/2018
1	Pathologic Constriction (Stenosis) 12/2018
1	Paralysis (Palsy) 12/2018
1	Hypoxia (Hypoxemia) 06/2018
1	Paraganglioma (Paragangliomas) 06/2018
1	Ependymoma 10/2017
1	Cerebral Hemorrhage 10/2017
1	Hemifacial Spasm 03/2017
1	Meningioma (Meningiomas) 11/2014

Drug/Important Bio-Agent (IBA)

6	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2021 - 06/2014
5	EnzymesIBA 01/2021 - 12/2015
3	Coenzymes (Enzyme Cofactors)IBA 01/2021 - 12/2015
2	NAD (NADH)IBA 01/2021 - 09/2016
2	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 01/2017
2	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2019
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 10/2017
2	Glucose (Dextrose)FDA LinkGeneric 05/2018 - 09/2016
2	Nicotinamide PhosphoribosyltransferaseIBA 01/2018 - 12/2015
2	alpha-hydroxyglutarateIBA 01/2018 - 12/2015
2	FluoridesIBA 11/2014 - 03/2013
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	Sirtuin 1IBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	SirtuinsIBA 01/2021
1	CRISPR-Associated Protein 9IBA 01/2021
1	HexokinaseIBA 12/2020
1	Alkylating AgentsIBA 11/2020
1	poly ADP-ribose glycohydrolaseIBA 11/2020
1	Glycoside Hydrolases (Endoglycosidases)IBA 11/2020
1	Diacetyl (Biacetyl)IBA 06/2020
1	copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)IBA 06/2020
1	Methionine (L-Methionine)FDA Link 01/2020
1	Anaplastic Lymphoma KinaseIBA 10/2019
1	LigandsIBA 01/2019
1	Immunoconjugates (Immunoconjugate)IBA 01/2019
1	rovalpituzumab tesirineIBA 01/2019
1	PolymersIBA 01/2019
1	AntigensIBA 01/2019
1	Erythropoietin FDA Link 01/2019
1	Succinate Dehydrogenase (Fumarate Reductase)IBA 06/2018
1	Deoxyglucose (2 Deoxy D glucose)IBA 06/2018
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 05/2018
1	N- (6- chlorophenoxyhexyl)- N''- cyano- N''- 4- pyridylguanidine (CHS 828)IBA 01/2018
1	Methotrexate (Mexate)FDA LinkGeneric 01/2018
1	Transaminases (Aminotransferases)IBA 01/2018
1	Glutamic Acid (Glutamate)FDA Link 01/2018
1	GlutaminaseIBA 01/2018
1	Small Interfering RNA (siRNA)IBA 09/2016
1	TransferasesIBA 09/2016
1	Niacinamide (Nicotinamide)FDA LinkGeneric 09/2016
1	nicotinate phosphoribosyltransferaseIBA 12/2015
1	FluorineIBA 11/2014
1	Telomerase (Telomerase Reverse Transcriptase)IBA 08/2013

Therapy/Procedure

6	Drug Therapy (Chemotherapy) 07/2021 - 01/2017
4	Therapeutics 01/2019 - 01/2017
2	Radiotherapy 07/2021 - 01/2021
2	Decompression 09/2019 - 12/2018
1	Molecular Targeted Therapy 01/2022
1	Transplantation 01/2019
1	Foraminotomy 12/2018
1	Traction 12/2018
1	Chemoradiotherapy 05/2018
1	Conservative Treatment 10/2017
1	Microvascular Decompression Surgery 03/2017